Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Citigroup Inc.    C

CITIGROUP INC.

(C)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Citi : Appointed as Depositary Bank for Stealth BioTherapeutics' ADR Programme

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/21/2019 | 07:47am EDT

Citi, acting through Citibank N.A., has been appointed by Stealth BioTherapeutics Corp. (“Stealth”) as depositary bank for its American Depositary Receipt (“ADR”) programme. Stealth’s ADRs trade on the Nasdaq Global Market under the symbol “MITO.” Each ADR represents 12 ordinary shares of Stealth.

“We are pleased to have been selected by Stealth as depositary bank for its Nasdaq listed ADR programme,” said Dirk Jones, Global Head of Issuer Services, at Citi. “We look forward to supporting the expansion of Stealth’s investor outreach through the expertise of our Investor Relations Advisory team and the breadth of our global equity distribution network.”

For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr.

About Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi

About Stealth BioTherapeutics

Stealth BioTherapeutics (“Stealth”) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body’s main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases, collectively known as primary mitochondrial diseases, and are also involved in many common age-related diseases. Stealth believes their lead product candidate, elamipretide, has the potential to treat both rare genetic and common age-related mitochondrial diseases. Stealth is studying elamipretide in the following primary mitochondrial diseases: primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy. The company is also studying elamipretide in dry age-related macular degeneration. Stealth’s other pipeline candidates include SBT-20, which is being evaluated for rare peripheral neuropathies, and SBT-272, which is being evaluated for rare neurodegenerative disease indications. The company has optimized its discovery platform to identify novel mitochondrial-targeted compounds, which may be nominated as therapeutic product candidates or utilized as scaffolds to deliver other compounds to mitochondria. Stealth’s mission is to be the leader in mitochondrial medicine, and the company has assembled a highly experienced management team, board of directors and group of scientific advisors to help them achieve this mission.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CITIGROUP INC.
10:18aCITI : Appointed as Depositary Bank for Mereo BioPharma's ADR Programme
BU
08:32aCITI : Releases 2018 Global Citi :zenship Report
BU
04:35aDeutsche Bahn asks for expressions of interest in Arriva by May 3
RE
04/23CITI : and ISS Launch High Frequency Connection for Proxymity Voting Platform
BU
04/17House Democrats Subpoenaed Nine Banks in Trump Finance Probe -- 2nd Update
DJ
04/17House Democrats Subpoenaed Nine Banks in Trump Finance Probe -- Update
DJ
04/17House Democrats Subpoenaed Nine Banks in Trump Finance Probe -- Update
DJ
04/17House Democrats Subpoenaed Nine Banks in Trump Finance Probe
DJ
04/17CITIGROUP INC : Change in Directors or Principal Officers, Submission of Matters..
AQ
04/17CITIGROUP : Declares Common Stock Dividend; Citigroup Declares Preferred Dividen..
BU
More news
Financials ($)
Sales 2019 74 432 M
EBIT 2019 32 181 M
Net income 2019 17 013 M
Debt 2019 -
Yield 2019 2,84%
P/E ratio 2019 9,18
P/E ratio 2020 8,06
Capi. / Sales 2019 2,18x
Capi. / Sales 2020 2,11x
Capitalization 162 B
Chart CITIGROUP INC.
Duration : Period :
Citigroup Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CITIGROUP INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 78,4 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Michael Louis Corbat Chief Executive Officer & Director
James Anthony Forese President & CEO-Institutional Clients Group
John C. Dugan Chairman
John C. Gerspach Chief Financial Officer
Anthony M. Santomero Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CITIGROUP INC.32.92%161 962
JP MORGAN CHASE & COMPANY16.37%369 412
INDUSTRIAL AND COMMERCIAL BANK OF CHINA9.83%298 756
BANK OF AMERICA22.04%287 721
CHINA CONSTRUCTION BANK CORPORATION16.01%240 299
WELLS FARGO2.76%215 061